HIF-1α and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Neoangiogenesis plays a crucial role in the progression of hepatocellular carcinoma (HCC), and concerns have been raised about the role of neoangiogenesis on the effectiveness of transarterial chemoembolization (TACE).
AIM: In this study, we aimed to evaluate Vascular Endothelial Growth Factor (VEGF) and Hypoxia-Inducible Factor-1α (HIF-1α) as circulating prognostic biomarkers in HCC patients treated with TACE.
METHODS: Blood samples were collected from 163 patients before (t0) and four weeks after TACE (t1).
RESULTS: Higher levels of VEGF after TACE were demonstrated (264.0 [78.7-450.8] vs. 278.6 [95.0-576.6] pg/mL; p < 0.0001). Responders to TACE had lower levels of VEGF than non-responders both at t0 (200.0 [58.9-415.8] vs. 406.6 [181.4-558.6] pg/mL; p = 0.006) and at t1 (257.3 [68.5-528.6] vs. 425.9 [245.2-808.3] pg/mL; p = 0.003), and in both groups there was an increase in VEGF compared to measurements before treatment (p = 0.001 and p = 0.005, respectively). VEGF was not associated with overall survival (OS), while patients with HIF-1α ≤ 0.49 ng/mL showed better prognosis (median OS 28.0 months [95% CI 19.7-36.3] vs. 17.0 months [95% CI 11.1-22.9]; p = 0.01). Moreover, HIF-1α was identified as an independent prognostic parameter.
CONCLUSIONS: VEGF and HIF-1α can be considered useful prognostic biomarkers in HCC patients treated with TACE.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - (2023) vom: 30. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pinto, Elisa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 02.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.dld.2023.09.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362794324 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362794324 | ||
| 003 | DE-627 | ||
| 005 | 20231226092001.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dld.2023.09.019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362794324 | ||
| 035 | |a (NLM)37783655 | ||
| 035 | |a (PII)S1590-8658(23)00963-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pinto, Elisa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HIF-1α and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Neoangiogenesis plays a crucial role in the progression of hepatocellular carcinoma (HCC), and concerns have been raised about the role of neoangiogenesis on the effectiveness of transarterial chemoembolization (TACE) | ||
| 520 | |a AIM: In this study, we aimed to evaluate Vascular Endothelial Growth Factor (VEGF) and Hypoxia-Inducible Factor-1α (HIF-1α) as circulating prognostic biomarkers in HCC patients treated with TACE | ||
| 520 | |a METHODS: Blood samples were collected from 163 patients before (t0) and four weeks after TACE (t1) | ||
| 520 | |a RESULTS: Higher levels of VEGF after TACE were demonstrated (264.0 [78.7-450.8] vs. 278.6 [95.0-576.6] pg/mL; p < 0.0001). Responders to TACE had lower levels of VEGF than non-responders both at t0 (200.0 [58.9-415.8] vs. 406.6 [181.4-558.6] pg/mL; p = 0.006) and at t1 (257.3 [68.5-528.6] vs. 425.9 [245.2-808.3] pg/mL; p = 0.003), and in both groups there was an increase in VEGF compared to measurements before treatment (p = 0.001 and p = 0.005, respectively). VEGF was not associated with overall survival (OS), while patients with HIF-1α ≤ 0.49 ng/mL showed better prognosis (median OS 28.0 months [95% CI 19.7-36.3] vs. 17.0 months [95% CI 11.1-22.9]; p = 0.01). Moreover, HIF-1α was identified as an independent prognostic parameter | ||
| 520 | |a CONCLUSIONS: VEGF and HIF-1α can be considered useful prognostic biomarkers in HCC patients treated with TACE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Angiogenesis | |
| 650 | 4 | |a Liver cancer | |
| 650 | 4 | |a Prognosis | |
| 700 | 1 | |a Pelizzaro, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Cardin, Romilda |e verfasserin |4 aut | |
| 700 | 1 | |a Battistel, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Palano, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Bertellini, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Kitenge, Maria Piera |e verfasserin |4 aut | |
| 700 | 1 | |a Peserico, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Farinati, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Francesco Paolo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver |d 2000 |g (2023) vom: 30. Sept. |w (DE-627)NLM108968790 |x 1878-3562 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:30 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dld.2023.09.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 30 |c 09 | ||